FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Abivax Positive Data with Ulcerative Colitis Drug

[ Price : $8.95]

Abivax announces new Phase 3 data showing that its lead drug candidate, obefazimod, achieved clinically meaningful improvements ac...

FDA OKs Arcutis Zoryve for Pediatric Eczema

[ Price : $8.95]

FDA approves an Arcutis Biotherapeutics supplemental NDA for Zoryve (roflumilast) cream 0.05% for treating mild to moderate atopic...

FDA Pilots Speedier Reviews for U.S.-Made Generics

[ Price : $8.95]

FDA unveils a new pilot program to prioritize the review of certain generic drug ANDAs in an effort to boost domestic pharmaceutic...

Makary Outlines Push to Modernize Drug Reviews

[ Price : $8.95]

FDA commissioner Marty Makary talks with CNNs Sanjay Gupta and says he wants to speed up the nations drug approval process without...

Brookings Questions FDAs New Voucher Program

[ Price : $8.95]

A new Brookings Institution commentary raises concerns about FDAs new Commissioners National Priority Voucher pilot program.

2nd Generic Mifepristone Approved, Prompting Backlash

[ Price : $8.95]

FDA approves the second generic copy of abortifacient mifepristone, a move that prompted mixed reactions from lawmakers and advoca...

Agency Posts Form-483 for India Vaccine Maker

[ Price : $8.95]

FDA posts a five-item FDA Form-483 after inspecting Covid-19 vaccine maker Serum Institute of Indias Maharashtra manufacturing fac...

Rocket Pharma Withdraws Gene Therapy BLA

[ Price : $8.95]

Rocket Pharmaceuticals withdraws its BLA for RP-L102 (mozafancogene autotemcel), an investigational gene therapy for treating Fanc...

Repatha Phase 3 Trial Hits Primary Endpoints

[ Price : $8.95]

Amgen says its Repatha met the primary endpoints in a landmark Phase 3 trial, making it the only PCSK9 inhibitor to demonstrate a ...

Grifols Barcelona Facility Gets FDA-483

[ Price : $8.95]

FDA posts a four-item Form FDA 483 that was issued to Laboratorios Grifols after a 7/2024 inspection of the firms drug manufacturi...